EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Gollins, Simon W
McDonald, Alec C
Myint, A Sun
AffiliationMount Vernon Cancer Centre, Mount Vernon Hospital, Middlesex, United Kingdom. firstname.lastname@example.org
MetadataShow full item record
AbstractPURPOSE: 5-Fluorouracil (5-FU) + mitomycin C (MMC)-based chemoradiotherapy is standard treatment for patients with epidermoid anal carcinoma. Clinical trials in other cancers have confirmed 5-FU can successfully be replaced by the oral fluoropyrimidine capecitabine. This phase II trial aimed to determine the feasibility, toxicity, and efficacy of capecitabine, MMC and radiotherapy (RT) in anal cancer patients. METHODS AND MATERIALS: Radiotherapy comprised the schedule of the UK Anal Cancer Trial (ACT) II trial (50.4 Gy in 28 fractions of 1.8 Gy). With MMC (12 mg/m2) on Day 1 and capecitabine on each RT treatment day in two divided doses (825 mg/m2 b.i.d). The endpoints were complete response at 4 weeks, local control at 6 months and toxicity. RESULTS: Thirty-one patients entered the trial. The median age was 61 years (range 45-86) with 14 males and 17 females. Compliance with chemotherapy with no dose interruptions or delays was 68%, and with RT was 81%. Eighteen (58%) patients completed both modalities of treatment as planned. Dose-limiting Grade 3 or 4 diarrhea was seen in 1 of 31 patients. Three patients experienced Grade 3 neutropenia. There were no treatment-related deaths. Four weeks following completion of chemoradiation, 24 patients (77%) had a complete clinical response, and 4 (16%) a partial response. With a median follow-up of 14 months, three locoregional relapses occurred. CONCLUSIONS: Capecitabine with MMC and RT in with patients anal carcinoma is well tolerated, with minimal toxicity and acceptable compliance. We recommend testing this schedule in future national Phase III studies in anal cancer.
CitationEXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. 2008, 72 (1):119-26 Int. J. Radiat. Oncol. Biol. Phys.
JournalInternational Journal of Radiation Oncology, Biology, Physics
- Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
- Authors: Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A
- Issue date: 2013 Apr 1
- Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients.
- Authors: Doci R, Zucali R, La Monica G, Meroni E, Kenda R, Eboli M, Lozza L
- Issue date: 1996 Dec
- Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
- Authors: Oliveira SC, Moniz CM, Riechelmann R, Alex AK, Braghirolli MI, Bariani G, Nahas C, Hoff PM
- Issue date: 2016 Mar
- Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
- Authors: Thind G, Johal B, Follwell M, Kennecke HF
- Issue date: 2014 May 29
- Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
- Authors: Goodman KA, Julie D, Cercek A, Cambridge L, Woo KM, Zhang Z, Wu AJ, Reidy DL, Segal NH, Stadler ZK, Saltz LB
- Issue date: 2017 Aug 1